Immunomedics, Inc.
(NASDAQ : IMMU)

( )
IMMU PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.86%122.371.1%$687.52m
GILDGilead Sciences, Inc.
-1.28%80.170.9%$652.57m
AMGNAmgen Inc.
-1.33%180.531.1%$453.70m
BIIBBiogen Inc.
-2.83%328.551.2%$418.30m
REGNRegeneron Pharmaceuticals, Inc.
-0.05%432.762.7%$322.07m
VRTXVertex Pharmaceuticals Incorporated
-2.31%151.061.9%$219.47m
INCYIncyte Corporation
-0.62%113.482.5%$198.97m
ALXNAlexion Pharmaceuticals, Inc.
-2.75%135.201.9%$188.62m
ILMNIllumina, Inc.
0.80%211.553.5%$133.98m
ALNYAlnylam Pharmaceuticals, Inc
0.76%115.5710.7%$131.21m
EXELExelixis, Inc.
-0.70%26.986.5%$126.80m
BLUEBluebird Bio, Inc.
-1.54%140.3517.3%$119.91m
SRPTSarepta Therapeutics, Inc.
-0.91%51.4716.9%$110.18m
BMRNBioMarin Pharmaceutical Inc.
-1.47%86.464.4%$109.02m
CLVSClovis Oncology, Inc.
-2.49%75.5716.5%$96.52m

Company Profile

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. The company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It markets and sells its products in the U.S. and throughout Europe. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.